Secondary Outcomes
intraoperative bleeding, injuries
RECURRENCE, INTRAOPERATIVE BLEEDING, SITE INFECTION, PATHOLOGIC FRACTURES, APPENDIX
Four (15%) of the children in the allograft and 6 (24%) in the bioactive glass group required a reoperation (surgery or an interventional radiographic procedure) for a recurrence during the follow-up (OR for bioactive glass = 1.74, 95% CI = 0.43 to 7.09, p = 0.50). A special feature of the reoperations in the patients receiving bioactive glass was a uniformly very difficult approach to recurrent cysts with a high-speed burr through the extremely hard mixture of glass and newly formed bone. Thermal tissue injuries were prevented with continuous saline solution irrigation during this process, which did not result into pathologic fractures.There were no growth disturbances (see Appendix), pathologic fractures, or deep surgical site infections. One (4%) of the patients in the bioactive glass group, who had a pelvic ABC, had intraoperative bleeding exceeding 50% of his blood volume. The MSTS score improved significantly from preoperatively to the 2-year follow-up in both the allograft group (from 23.4 to 29.1, p = 0.010) and bioactive glass group (from 22.4 to 28.7, p = 0.013), and the difference at 2 years was not significant (Table II).